Biomarkers offer great potential for improving management of cancer at every point from screening and detection, to diagnosis, staging, prognosis, and the assessment of treatment response.
Krystal Knapp
Advertisement
Articles by Krystal Knapp
As personalized medicine occupies a growing role in the pharmaceutical pipeline, major companies are changing their research and development paradigms.
The latest cancer study. A book-signing event. A hospital mural project. These topics and more are all fodder for the Fox Chase Cancer Center's Facebook page
Advertisement
Latest Updated Articles
Socializing Medicine: Oncology Joins Facebook EraPublished: March 24th 2011 | Updated:
Industry Testing New Models for Developing BiomarkersPublished: August 10th 2011 | Updated:
The Great Biomarker Chase: Promise & Pitfalls Along the Path to Personalized CarePublished: August 16th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5